Inquis Medical’s Aventus Thrombectomy System’s Pivotal Trial Completes Enrollment

January 13, 2025—Inquis Medical, which is developing therapies for venous thromboembolic diseases, announced the completion of patient enrollment in its AVENTUS clinical trial. The pivotal investigational device exemption (IDE) trial is evaluating the safety and efficacy of the company’s Aventus thrombectomy system for the treatment of pulmonary embolism (PE).

According to the company, the multicenter, prospective, single-arm trial enrolled 130 patients with intermediate-risk PE at more than 20 clinical sites across the United States.

Jun Li, MD, and Saher Sabri, MD, are national coprincipal investigators of the trial.

“This trial is a key step toward delivering a more streamlined, efficient, and precise thrombectomy solution for treating life-threatening blood clots,” commented Dr. Li in the company’s press release. “The Aventus system stands out with its unique combination of streamlined blood return, directional aspiration, and the elimination of multiple dilator or wire exchanges, offering an elegant and efficient solution for removing thrombi in PE patients.”

Dr. Sabri added, “The AVENTUS pivotal trial represents a new option for treating PE. We are grateful to the 130 patient volunteers in this trial and our colleagues who helped rapidly enroll participants reflecting the clinical community’s strong dedication to advancing care in this field.”

Dr. Li is Codirector of the Vascular Center and Pulmonary Embolism Response Team at University Hospitals Harrington Heart & Vascular Institute in Cleveland, Ohio.

Dr. Sabri is Professor of Radiology at Georgetown University School of Medicine, Chief of Interventional Radiology at MedStar Health, and Division Chief of Interventional Radiology at MedStar Georgetown University Hospital in Washington, DC.